```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
 NEWS 20  APR 15  WPIDS, WPINDEX, and WPIX enhanced with new
                  predefined hit display formats
 NEWS 21  APR 28  EMBASE Controlled Term thesaurus enhanced
 NEWS 22  APR 28  IMSRESEARCH reloaded with enhancements

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
```

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:36:56 ON 01 MAY 2008

=>
=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.21        0.21

FILE 'REGISTRY' ENTERED AT 06:37:06 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2008  HIGHEST RN 1018615-45-6
DICTIONARY FILE UPDATES:  30 APR 2008  HIGHEST RN 1018615-45-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10530840.str
```



```
chain nodes :
10  11  12  13  14  15
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
7-12  9-10  10-11  12-13  13-14  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9
exact/norm bonds :
5-7  6-9  7-8  7-12  8-9  9-10  10-11  12-13  13-14  13-15
normalized bonds :
```

1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 06:37:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   40 TO ITERATE

100.0% PROCESSED   40 ITERATIONS   13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 421 TO   1179
PROJECTED ANSWERS: 44 TO   476

L2   13 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:37:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   700 TO ITERATE

100.0% PROCESSED   700 ITERATIONS   195 ANSWERS
SEARCH TIME: 00.00.01

L3   195 SEA SSS FUL L1

```
=> s l3 and caplus/lc
      56590141 CAPLUS/LC
L4          182 L3 AND CAPLUS/LC

=> s l3 not l4
L5           13 L3 NOT L4

=> d l5 1-13
```

L5 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 956088-08-7 REGISTRY
ED Entered STN: 28 Nov 2007
CN 1H-Indazole-3-carboxylic acid, 1-[2-(1,3-benzodioxol-5-ylamino)-2-oxoethyl]-, methyl ester (CA INDEX NAME)
MF C18 H15 N3 O5
SR Chemical Library
Supplier: TimTec, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 945145-44-8 REGISTRY
ED Entered STN: 21 Aug 2007
CN 1H-Indazole-3-carboxylic acid, 1-[2-oxo-2-[(2-oxo-2-phenylethyl)amino]ethyl]-, methyl ester (CA INDEX NAME)
MF C19 H17 N3 O4
SR Chemical Library
Supplier: Scientific Exchange, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 933028-88-7 REGISTRY
ED Entered STN: 29 Apr 2007
CN 1H-Indazole-1-acetamide, N-[(4-chlorophenyl)methyl]-3-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)
MF C21 H21 Cl N4 O2
SR Chemical Library
Supplier: Aurora Fine Chemicals
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 932992-46-6 REGISTRY
ED Entered STN: 27 Apr 2007
CN 1H-Indazole-1-acetamide, N-(4-chlorophenyl)-3-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)
MF C20 H19 Cl N4 O2
SR Chemical Library
Supplier: Aurora Fine Chemicals
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869793-64-2 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide, N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl]- (CA INDEX NAME)
MF C27 H37 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869793-60-8 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide, 3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl]-N-[[4-fluorophenyl)methyl]-5-[[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]- (CA INDEX NAME)
MF C31 H31 F2 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 869793-56-2 REGISTRY
ED Entered STN: 13 Dec 2005
CN 1H-Indazole-1-carboxamide, 3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl]-N-[(3-methoxyphenyl)methyl]-5-[[[[(3-methoxyphenyl)methyl]amino]carbonyl]amino]- (CA INDEX NAME)
MF C33 H37 N7 O5
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865886-25-5 REGISTRY
ED Entered STN: 24 Oct 2005
CN Carbamic acid, [3-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-1-[[(1-methylethyl)amino]carbonyl]-1H-indazol-5-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H32 N6 O4
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865985-93-4 REGISTRY
ED Entered STN: 24 Oct 2005
CN 1H-Indazole-3,5-dicarboxamide, N3-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-N1-propyl-5-[[(propylamino)carbonyl]amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H33 N7 O3
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865985-91-2 REGISTRY
ED Entered STN: 24 Oct 2005
CN 1H-Indazole-3,5-dicarboxamide, N3-(3R)-1-azabicyclo[2.2.2]oct-3-yl-N1-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H37 N7 O3
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-44-4 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, N-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]- (CA INDEX NAME)
MF C27 H37 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-40-2 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, N-[(4-fluorophenyl)methyl]-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]- (CA INDEX NAME)
MF C33 H31 F2 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2008 ACS on STN
RN 858661-36-6 REGISTRY
ED Entered STN: 07 Aug 2005
CN 1H-Indazole-1-carboxamide, 3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[(propylamino)carbonyl]amino]- (CA INDEX NAME)
MF C23 H33 N7 O3
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   209.51     209.72

FILE 'CAPLUS' ENTERED AT 06:37:52 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 May 2008  VOL 148 ISS 18
FILE LAST UPDATED: 30 Apr 2008  (20080430/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 06:36:56 ON 01 MAY 2008)

     FILE 'REGISTRY' ENTERED AT 06:37:06 ON 01 MAY 2008
L1               STRUCTURE UPLOADED
L2           13 S L1
L3          195 S L1 FULL
L4          182 S L3 AND CAPLUS/LC
L5           13 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 06:37:52 ON 01 MAY 2008

=> s l4
L6           15 L4

=> d ibib abs hitstr 1-15
```

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:319632 CAPLUS
DOCUMENT NUMBER: 148:331704
TITLE: Oxoquinazoline compounds as ophthalmic compositions for treating ocular hypertension and their preparation
INVENTOR(S): Doherty, Jansa B.; Shu, Min; Shen, Dong-Ming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 49pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006023299	A2	20060313	WO 2005-US31213	20050831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2004-8422249 P	20040965

GI





II

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1011485-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-66-7 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 4-[butyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]butyl ester (CA INDEX NAME)



L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB This invention relates to potent potassium channel blocker compds. of formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans. Compds. of formula I wherein W and Y1 are independently (un)substituted (mono/di/tria)hydrazyl, (un)substituted (mono/bi/tria)quinazolyl, (un)substituted (mono/bi/tri)indolyl, (un)substituted (mono/bi/tria)benzofuranyl, (un)substituted naphthalenyl, etc.; Y1 and Y2 are independently Q and R2; Q and Q' are independently O, NR and deriv., and a bond; W is (un)substituted C1-12 alkyl diradical optionally interrupted by C5-10 aryl, C5-10 heteroaryl, et c., X and X' are independently (CHR7)q-2, R7 is H, C1-4 alkyl, (CR2)0-3-CO2R and deriv., and (CR2)0-3-NR2 and deriv.; and their pharmaceutically acceptable salts, hydrolyzable esters, enantiomers, diastereoisomers and mixture thereof, are claimed. Example compound II was prepared by coupling of (3-tert-butyl-7-methoxy-2-oxoquinazolin-1(2H)-yl)acetic acid with N-butyl-3-hydroxy-2,2-dimethylpropylamine. All the invention compds. were evaluated for their potassium channel inhibitory activity (some data given).

IT 1011485-64-5P 1011485-67-8P 1011485-68-9P 1011485-69-0P 1011485-70-3P 1011485-71-4P 1011485-72-5P 1011485-73-6P 1011485-74-7P 1011485-75-8P 1011485-76-9P 1011485-77-0P 1011485-78-1P 1011485-79-2P 1011485-81-8P 1011485-82-9P 1011485-83-0P 1011485-84-1P 1011485-85-2P 1011485-86-3P 1011485-87-4P 1011485-88-5P 1011485-89-6P 1011486-00-2P 1011486-01-3P 1011486-02-4P 1011486-03-5P 1011486-04-6P 1011486-05-7P 1011486-06-8P 1011486-07-9P 1011486-08-0P 1011486-09-1P 1011486-10-4P 1011486-11-5P 1011486-12-6P 1011486-13-7P 1011486-14-8P 1011486-15-9P 1011486-16-0P 1011486-17-1P 1011486-18-2P 1011486-19-3P 1011486-20-6P 1011486-21-7P 1011486-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxoquinazoline compds. as potassium channel blockers and their ophthalmic compns. for treating ocular hypertension)
RN 1011485-64-5 CAPLUS
CN 2-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]ethyl ester (CA INDEX NAME)

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 1011485-67-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-68-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 4-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]butyl ester (CA INDEX NAME)



RN 1011485-69-0 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-(2-methyl-1-oxopropyl)-, 3-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl](3-methylbutyl)amino]-2,2-dimethylpropyl ester (CA INDEX NAME)



RN 1011485-70-3 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-[2-methyl-1-oxopropyl]-, 3-(butyl[2-(6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino)-2,2-dimethylpropyl ester (CA INDEX NAME)

RN 1011485-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1011485-73-8 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-[2-methyl-1-oxopropyl]-, 4-[cyclohexyl[2-[6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino]butyl ester (CA INDEX NAME)



RN 1011485-74-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 6-methoxy-3-[2-methyl-1-oxopropyl]-, 2-[ethyl[2-[6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino]ethyl ester (CA INDEX NAME)



RN 1011485-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-76-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-77-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-90-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-91-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-92-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-93-0 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N-[2-[[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl]-N-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)





RN 1011485-97-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-98-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

RN 1011485-94-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-[2-[ethyl[2-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]acetyl]amino]ethyl]-6-methoxy-N-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 1011485-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-96-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011485-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-00-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-61-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-62-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-4-methoxy-N-[4-[[2-[6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino]butyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 1011486-96-8 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-N-[6-[[2-[6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino]hexyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 1011486-67-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-63-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-64-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-65-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-68-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-69-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-N-[2-[2-[[2-[6-methoxy-3-[2-methyl-1-oxopropyl]-1H-indazol-1-yl]acetyl]amino]ethoxy]ethyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 1011496-09-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B

RN 1011496-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011496-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011496-15-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 3-[2,2-dimethyl-1-oxopropyl]-6-methoxy-, 3-[butyl[2-[3-[2,2-dimethyl-1-oxopropyl]-6-methoxy-1H-indazol-1-yl]acetyl]amino]-2,2-dimethylpropyl ester (CA INDEX NAME)



RN 1011496-16-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 1011496-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011496-14-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

RN 1011496-17-1 CAPLUS
CN 1H-Indazole-1-acetic acid, 3-[2,2-dimethyl-1-oxopropyl]-6-methoxy-, 2-[[2-[3-[2,2-dimethyl-1-oxopropyl]-6-methoxy-1H-indazol-1-yl]acetyl]ethylamino]ethyl ester (CA INDEX NAME)



RN 1011496-18-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011496-29-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-39-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-51-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1011486-52-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

ACCESSION NUMBER: 2007:384736 CAPLUS
DOCUMENT NUMBER: 146:402148
TITLE: Preparation of azabicyclic derivatives of indazoles, benzothiazoles, benzisoxazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines for therapeutic use as α7-nAChR receptor activators

INVENTOR(S): Schumacher, Richard; Dance, Mihaela Diana; Ma, Jiangou; Herbert, Brian; Nguyen, Truc Minh; Xie, Wenge; Tehim, Ashok

PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 283pp.
CODEN: PIXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007078567	A1	20070405	WO 2006-US37142	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070078147	A1	20070405	US 2006-525213	20060922
PRIORITY APPLN. INFO.:			US 2005-719552P	P 20050923
			US 2006-791881P	P 20060414

OTHER SOURCE(S): MARPAT 146:402148
GI

AB N-azabicyclo[2.2.2]octyl-heterocyclic amide deriva., such as I [R = heterocyclyl, such as those cited in the title], were prepared as α7 nicotinic acetylcholine receptor (α7-nAChR) ligands which activate or enhance defective or malfunctioning nAChR activity, especially of the brain,
and are useful in the treatment of psychotic disease, neurodegenerative

disease and conditions of memory and/or cognition impairment. These diseases and conditions may include schizophrenia, anxiety, mania, depression, manic depression, Tourette's syndrome, Parkinson's disease, Huntington's disease, Alzheimer's disease, Lewy body dementia, amyotrophic
lateral sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, attention deficit hyperactivity disorder (ADHD) and mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia, HIV and/or cardiovascular diseases. These diseases may further include alc. and nicotine addiction, pain, jet lag, obesity, diabetes, vascular dementia (VaD), age-assocd. cognitive decline (AACD), amnesia assocd. with open-heart-surgery, cardiac arrest, general anesthesia, memory deficits from exposure to anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndromes, narcolepsy, AIDS-related dementia, epilepsy-related cognitive impairment, Down's syndrome, alcoholism related
dementia, drug/substance induced memory impairments and dementia pugilistica (boxer syndrome). Thus, amide II was prepd. via an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride with Et 6-bromobenzisoxazole-3-carboxylate in EtOH using N,N-diisopropylethylamine. The prepd. amides were assayed for α7-nAChR binding affinity.

IT 932702-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TSU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclic deriv. of indazoles, benzothiazoles, benzisoxazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines for therapeutic use as α7-nAChR receptor activators)

RN 932702-78-1 CAPLUS
CN 1H-Indazole-3,3-dicarboxamide, N1,N3-bis[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-
(CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:513788 CAPLUS
DOCUMENT NUMBER: 145:27984
TITLE: 3-(3,4,5-Trimethoxybenzoyl)indazoles and related compounds as tubulin binding anticancer agents and prodrugs thereof; Their preparation, pharmaceutical composition and use for treatment of cancers
INVENTOR(S): Mattesond, Mark; Duan, Jian-Xin; Cai, Xiaohong
PATENT ASSIGNEE(S): Threshold Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006037946	A2	20060601	WO 2005-GB4095	20051117
WO 2006037946	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2005309761	A1	20060601	AU 2005-309761	20051117
CA 2587210	A1	20060601	CA 2005-2587210	20051117
EP 1819335	A2	20070822	EP 2005-826490	20051117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101094855	A	20071226	CN 2005-80045633	20051117
MX 2007006102	A	20070711	MX 2007-6102	20070521
IN 2007DN04648	A	20070917	IN 2007-DN4648	20070618
NO 2007003211	A	20070822	NO 2007-3211	20070622
KR 2007086595	A	20070927	KR 2007-714242	20070622
PRIORITY APPLN. INFO.:			US 2004-630422P	P 20041122
			US 2005-729328P	P 20051014
			WO 2005-GB4095	W 20051117

OTHER SOURCE(S): MARPAT 145:27984
GI

RN 889134-63-8 CAPLUS
CN 1H-Indazole-1-acetamide, 7-methoxy-3-(3,4,5-trimethoxybenzoyl)- (CA INDEX NAME)



L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Tubulin binding compds. of formula I and hypoxia activated prodrugs of known tubulin binding compds. useful for treating cancer and other hyperproliferative diseases are disclosed. Compds. of formula I wherein A is (un)substituted indazoline, (un)substituted imidazopyridine, (un)substituted pyrazolopyridine, (un)substituted triazolopyridine, (un)substituted arylene, etc.; X is O, NRR2 and derivs., and NOR and derivs.; Q3 - Q5, and Q8 are independently H, halo, amino, C1-6 (mono/di/alkylamino, OR, C1-6 alkoxy, NO2, CN, (hetero)aryl, etc.; and their tautomers, isomers, racemic, non-racemic mixts. of isomers, polymorphs, hydrates, or pharmaceutically acceptable salts and solvates there of is claimed. Example compound II was prepared by treating 3-(3,4,5-trimethoxybenzoyl)-7-iodo-6-methoxyindazole with propargyl alc. All the invention compds. were evaluated for their tubulin binding anticancer activity. Compound II exhibited GI50 values of 870 nM after 2 h, and 10 nM after 3 days against H460 cell line. Compound II also showed GI50 values of 0.3 nM against MES-SA, 1.6 nM against, MES-SA/DX5, 1.9 nM against H729, and 2.5 nM against 747D.

IT 889134-57-0P 889134-63-8P
RLs PAC (Pharmacological activity); SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (trimethoxybenzoyl)indazolines and related compds. as tubulin binding anti cancer agents and prodrugs thereof useful for treatment of cancers)

RN 889134-57-0 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(3,4,5-trimethoxybenzoyl)- (CA INDEX NAME)

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:164871 CAPLUS
DOCUMENT NUMBER: 144:254122
TITLE: Preparation of indazole derivatives and ophthalmic compositions for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Shen, Dong-Ming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020003	A2	20060223	WO 2005-US25136	20050715
WO 2006020003	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005274972	A1	20060223	AU 2005-274972	20050715
CA 2574078	A1	20060223	CA 2005-2574078	20050715
EP 1771170	A2	20070411	EP 2005-771451	20050715
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1989983	A	20070627	CN 2005-80024538	20050715
JP 2008507511	T	20080313	JP 2007-521841	20050715
US 20090033951	A1	20090207	US 2006-630172	20061219
IN 2006CN04793	A	20071005	IN 2006-CN4793	20061228
PRIORITY APPLN. INFO.:			US 2004-589444P	P 20040720
			WO 2005-US25136	W 20050715

OTHER SOURCE(S): CASREACT 144:254122; MARPAT 144:254122
GI



AB Title compds. I [M, M1, M2 = CH or N; Z = N or C, when Z = N then the bond
between Y and Z is a single bond and between X and Y resp. represents CR1-N, CH2-CH2a, CR1=CR2, or N-CR1, and when Z = C then X = O or S, Y represents CR1 and the bond between Y and Z is a double bond; R4 and R5 independently = H, OH, alkoxy, etc., Q = unsatd. phosphonate derivative or
substituted carbonyl alkyl derivative; R1 = OH, alkoxy,, unsatd. phosphonate
derivative, etc., R1a = H, (un)substituted alkyl, cycloalkyl, etc.], and their
pharmaceutically acceptable salts, are prepared and disclosed as potassium
channel blockers suitable for ophthalmic compns. fore treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. Thus, e.g., II was prepared by amidation
of [5-isobutyryl-6-methoxy-1H-indazol-1-yl]acetic acid (preparation given) with
di-n-butylamine. In assays for evaluating ability to block potassium
channels, I was determined to possess IC50's in the range of about 1nM to about
20 uM. Thus invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

IT 877144-23-3P 877144-10-0P 877144-11-1P
877144-12-2P 877144-13-3P 877144-14-4P
877144-15-5P 877144-16-6P 877144-17-7P
877144-18-8P 877144-21-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. and ophthalmic compns. thereof for treating
ocular hypertension)

RN 877144-23-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-13-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-cyclohexyl-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-14-4 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N,N-dipropyl- (CA INDEX NAME)



RN 877144-15-5 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-10-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N,N-bis(2-methylpropyl)- (CA INDEX NAME)



RN 877144-12-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(cyclopropylmethyl)-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N-propyl- (CA INDEX NAME)



RN 877144-16-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-N-(3-methylbutyl)-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-17-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-6-methoxy-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]-N-propyl- (CA INDEX NAME)



RN 877144-18-8 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N,N-bis(3-methylbutyl)-3-[2-methyl-1-(phosphonooxy)-1-propen-1-yl]- (CA INDEX NAME)



RN 877144-23-3 CAPLUS
CN 1H-Indazole-3-acetamide, N-[3,3-dimethylbutyl]-6-methoxy-3-[2-methyl-1-[phosphonooxy]-3-propen-1-yl]-N-propyl- (CA INDEX NAME)



IT 877144-28-0P 877144-29-1P 877144-30-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. and ophthalmic compns. thereof for treating
ocular hypertension)
RN 877144-28-0 CAPLUS
CN 1H-Indazole-3-acetamide, N-[3,3-dimethylbutyl]-N-ethyl-6-methoxy-3-[2-methyl-3-oxopropyl]- (CA INDEX NAME)



RN 877144-29-1 CAPLUS

CN 1H-Indazole-3-acetamide, 3-(2-bromo-2-methyl-1-oxopropyl)-N-[3,3-dimethylbutyl]-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 877144-30-4 CAPLUS
CN Phosphoric acid, 3-[3-[2-[(3,3-dimethylbutyl)ethylamino]-2-oxoethyl]-6-methoxy-1H-indazol-3-yl]-2-methyl-1-propen-1-yl diethyl ester (CA INDEX NAME)



ACCESSION NUMBER:	2005:1241229 CAPLUS
DOCUMENT NUMBER:	144:6818
TITLE:	Indazoles, benzothiazoles, 1,2-benzisoxazoles, 1,2-benzisothiazole, and chromones as α7 nicotinic receptor agonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S):	Xie, Wenge; Herbert, Brian; Schumacher, Richard A.; Ma, Jianyou; Nygren, Trac Minh; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S):	Memory Pharmaceuticals Corporation, USA
SOURCE:	PCT Int. Appl., 143 pp. CODEN: PIXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111038	A2	20051124	WO 2005-US15937	20050506
WO 2005111038	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005243147	A1	20051124	AU 2005-243147	20050506
CA 2565984	A1	20051124	CA 2005-2565984	20050506
US 2005272735	A1	20051208	US 2005-123719	20050506
EP 1749548	A2	20070214	EP 2005-747486	20050506
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005009212	A	20071016	BR 2005-10212	20050506
JP 2007538013	T	20071227	JP 2007-511654	20050506
MX 2006PA12880	A	20070126	MX 2006-PA12880	20061107
IN 2006DN04854	A	20070831	IN 2006-DN4854	20061117
NO 2006085162	A	20070202	NO 2006-85162	20061206
KR 2007015807	A	20070205	KR 2006-725825	20061206
CN 1211422E	A	20080213	CN 2005-80031304	20070108
PRIORITY APPLN. INFO.:			US 2004-568696P	P 20040507
			US 2004-574712P	P 20040527
			US 2004-626469P	P 20041110
			WO 2005-US15937	W 20050506
			US 2005-568696P	P 20050507

OTHER SOURCE(S): CASREACT 144:6818; MARPAT 144:6818
GI



AB The invention relates to heteroaryl-substituted azabicyclic compds., e.g.,

I or II, which are ligands for nicotinic acetylcholine receptors (nAChR) and can be used for the activation of nAChRs and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. In compds. I and II,

R is



CH2, C=O, or C=S; m is 1 or 2; Y is O or S; X1 to X4 are independently selected from N and (un)substituted C, wherein at most one of X1 to X4 is N, X5 and X6 are independently selected from CH, fluoro-substituted C1-6 alkoxy-C, and heterocyclyl-C, wherein no more than one of X5 and X6 is



CH2;

X7 is CH or N; and R is H, (halo)-C1-4 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, and C1-6 alkyl-C6-10 aryl. The invention also relates to

the preparation of the heteroaryl-substituted diazabicyclic compds., pharmaceutical compns. comprising those compds. and a pharmaceutically acceptable carrier, as well as to the use of the compns. as agonists for the α7 nAChR subtype. Acylation of 3-methoxyphosphonol with oxalyl chloride followed by cyclization gave benzothiophenedione III, which underwent oxidative cleavage resulting in the formation of benzoisothiazolecarboxamide IV. Alkaline hydrolysis of IV to the carboxylic

acid was followed by coupling with 1,4-diazabicyclo[3.2.2]nonane to give compound V. The preferred compds. of the invention express binding affinities of 5 nM to 2.5 μM (no data).

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 869783-57-3P, 3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-(3-methoxybenzyl)-5-[[[3-methoxybenzyl]amino]carbonyl]amino]-1H-indazole-1-carboxamide formate 869783-61-9P, 3-(1,4-Diazabicyclo[3.2.2]non-

4-ylcarbonyl)-N-[4-fluorobenzyl]-5-[[[4-fluorobenzyl]amino]carbonyl]amino]-1H-indazole-1-carboxamide formate 869783-65-3P, N-Cyclopentyl-5-[[[cyclopentylamino]carbonyl]amino]-3-(1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazole-1-carboxamide formate RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted diazabicyclo[3.2.2]nonanes as a7 nicotinic receptor agonists)
RN 869783-57-3 CAPLUS
CN Formic acid, compd. with 3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-[(3-

methoxyphenyl)methyl]-5-[[[(3-methoxyphenyl)methyl]amino]carbonyl]amino]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-56-2
CMF C33 H37 N7 O5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-61-9 CAPLUS
CN Formic acid, compd. with 3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-N-[(4-

fluorophenyl)methyl]-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-1H-

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2

CRN 64-18-6
CMF C H2 O2

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-60-8
CMF C31 H31 F2 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 869783-65-3 CAPLUS
CN Formic acid, compd. with N-cyclopentyl-5-[[[cyclopentylamino)carbonyl]amin o]-3-[1,4-diazabicyclo[3.2.2]non-4-ylcarbonyl)-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 869783-64-2
CMF C27 H37 N7 O3

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:1075795 CAPLUS
DOCUMENT NUMBER:	143:347334
TITLE:	Preparation of quinuclidine indazole, benzothiazole, benzisothiazole and benzisoxoles as ligands for the a7 nicotinic acetylcholine receptor
INVENTOR(S):	Xie, Wenge; Herbert, Brian; Schumacher, Richard; Nguyen, Truc Minh; Ma, Jianguo; Gauss, Carla Maria; Tehim, Ashok
PATENT ASSIGNEE(S):	Memory Pharmaceuticals Corporation, USA
SOURCE:	PCT Int. Appl., 300 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092890	A2	20051006	WO 2005-US10120	20050325
WO 2005092890	A3	20060202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005227324	A1	20051006	AU 2005-227324	20050325
CA 2560741	A1	20051006	CA 2005-2560741	20050325
US 20050234095	A1	20051020	US 2005-89533	20050325
EP 1735306	A2	20061227	EP 2005-745168	20050325
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101001856	A	20070718	CN 2005-80016762	20050325
BR 2005008771	A	20070814	BR 2005-8771	20050325
JP 2007530590	T	20071101	JP 2007-505233	20050325
MX 2006PA10552	A	20070116	MX 2006-PA10552	20060922
NO 2006004826	A	20061220	NO 2006-4826	20061024
KR 2007014406	A	20070202	KR 2006-7020695	20061024
PRIORITY APPLN. INFO.:			US 2004-555951P	P 20040325
			US 2004-616033P	P 20041006
			WO 2005-US10120	W 20050325
OTHER SOURCE(S):	MARPAT 143:347334			
GI				



II

AB Quinuclidine derivs. of formula I [Y = NR1C(X)A, C(X)NR1A, NR1CH2A, CH2NR1A; A = (substituted) indazole, benzothiazole, benzoisothiazole or benzisoxazole; X = O, S; R1 = H, alkyl, haloalkyl, cycloalkyl, cycloalkyl-alkyl] are prepared as ligands for nicotinic acetylcholine receptors (nACh receptors), especially the α7 nACh receptor subtype. The compds. can be used for the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Thus, II was prepared The binding affinities of the prepared compds. were between 2 nM and 25 μM.

IT 865885-39-9P 865885-90-1P 865885-92-3P
865885-94-5P 865886-26-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinuclidine indazole, benzothiazole, benzoisothiazole and benzisoxazole derivs. as ligands for α7 nACh receptor subunit)

RN 865885-39-9 CAPLUS
CN 1H-Indazole-1,3-dicarboxamide, N3-[(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-[[3-methoxyphenyl]methyl]-5-[[[[3-methoxyphenyl]methyl]amino]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



O=C(H)N-OH

RN 865885-94-5 CAPLUS
CN Formic acid, compd. with N3-[(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-propyl-5-[[(propylamino)carbonyl]amino]-1H-indazole-1,3-dicarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865885-93-4
CMF C23 H33 N7 O3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=C(H)N-OH

RN 865886-26-4 CAPLUS
CN Carbamic acid, [3-[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-1-[(1-methylethyl)amino]carbonyl]-1H-indazol-5-yl]-, 1-methylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 865884-25-5
CMF C25 H32 N6 O4

Absolute stereochemistry.

RN 865885-90-1 CAPLUS
CN 1H-Indazole-1,3-dicarboxamide, N3-[(3S)-1-azabicyclo[2.2.2]oct-3-yl-N1-[[4-fluorophenyl]methyl]-5-[[[[(4-fluorophenyl]methyl]amino]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865885-92-3 CAPLUS
CN Formic acid, compd. with N3-[(3R)-1-azabicyclo[2.2.2]oct-3-yl-N1-cyclopentyl-5-[[(cyclopentylamino)carbonyl]amino]-1H-indazole-1,3-dicarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865885-91-2
CMF C27 H37 N7 O3

Absolute stereochemistry.

CM 2

CRN 64-18-6
CMF C H2 O2

CM 2

CRN 64-18-6
CMF C H2 O2

O=C(H)N-OH

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:612352 CAPLUS
DOCUMENT NUMBER: 143:133366
TITLE: Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
INVENTOR(S): Xie, Wenge; Herbert, Brian; Ma, Jianguo; Nguyen, Truc Minh; Schumacher, Richard A.; Gauss, Carla-Maria; Tehim, Ashok
PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061760	A2	20050714	WO 2004-US42852	20041222
WO 2005061760	A3	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004309367	A1	20050714	AU 2004-309367	20041222
CA 2550469	A1	20050714	CA 2004-2550469	20041222
US 20050176754	A1	20050811	US 2004-18429	20041222
EP 1697378	A2	20060906	EP 2004-814981	20041222
EP 1697378	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1918167	A	20070221	CN 2004-80041966	20041222
BR 2004017923	A	20070307	BR 2004-17923	20041222
JP 2007515424	T	20070614	JP 2006-545644	20041222
ES 2295933	T3	20080416	ES 2004-814981	20041222
IN 2006DN03547	A	20070831	IN 2006-DN3547	20060620
MX 2006PA07168	A	20060907	MX 2006-PA7168	20060622
NO 2006002392	A	20060921	NO 2006-2392	20060721
PRIORITY APPLN. INFO.:			US 2003-530891P	P 20031222
			US 2004-606897P	P 20040903
			WO 2004-US42852	W 20041222

OTHER SOURCE(S): MARPAT 143:133366
AB The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChRs), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAMES)

CM 3

CRN 858641-40-2
CMF C31 H33 F2 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 858641-45-7 CAPLUS
CN Formic acid, compd. with N-cyclopentyl-N-[(cyclopentylamino)carbonyl]amin o]-3-[(5-methyl-2,3-dihydrocyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 858641-44-6
CMF C27 H37 N7 O3

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
invention relates to novel compds. for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the
α7 nAChR subtype, methods of prepg. such compds., compns. containg. such compds., and methods of use thereof.
IT 858641-37-7P, 3-[(5-Methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[[propylamino)carbonyl]amino]-1H-indazole-1-carboxamide hydroformate 858641-41-3P, N-(4-Fluorobenzyl)-5-[[[(4-fluorobenzyl)amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide hydroformate 858641-45-7P, N-Cyclopentyl-5-[[[cyclopentylamino)carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide hydroformate
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles preparation and uses as α7 nicotinic receptor ligands for treating various nervous system diseases)
RN 858641-37-7 CAPLUS
CN Formic acid, compd. with 3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-N-propyl-5-[[propylamino)carbonyl]amino]-1H-indazole-1-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 858641-36-6
CMF C23 H33 N7 O3



CM 2

CRN 64-18-6
CMF C H2 O2

RN 858641-42-3 CAPLUS
CN Formic acid, compd. with N-[(4-fluorophenyl)methyl]-5-[[[(4-fluorophenyl)methyl]amino]carbonyl]amino]-3-[(5-methyl-2,5-diazabicyclo[2.2.2]oct-2-yl)carbonyl]-1H-indazole-1-carboxamide (1:1)
(CA

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 2

CRN 64-18-6
CMF C H2 O2

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:259877 CAPLUS
DOCUMENT NUMBER: 142:336354
TITLE: Preparation of indazole derivatives as potassium channel blockers for treating ocular hypertension
INVENTOR(S): Chen, Mary Kay; Doherty, James B.; Lin, Lupeng; Natarajan, Swaminathan; Tymebor, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005025568	A1	20050324	WO 2004-US28351	20040831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004271178	A1	20050324	AU 2004-271178	20040831
CA 2537436	A1	20050324	CA 2004-2537436	20040831
EP 1663223	A1	20060607	EP 2004-782774	20040831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
CN 1842335	A	20061004	CN 2004-80024357	20040831
JP 2007504278	T	20070301	JP 2006-525401	20040831
US 20070027128	A1	20070201	US 2006-570231	20060228
PRIORITY APPLN. INFO.:			US 2003-500090P	P 20030904
			WO 2004-US28351	W 20040831

OTHER SOURCE(S): CASREACT 142:336354; MARPAT 142:336354
GI



RN 695206-77-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-(2-hydroxyethoxy)-3-pyridinyl)carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-89-4 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-diethyl-3-[(6-(2-hydroxyethyl)-3-pyridinyl)carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-91-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-(2-hydroxyethyl)-3-pyridinyl)carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





AB Indazoles I [R, R1 = H, (un)substituted OH, OCOR, NH2, NO2N, alkyl, CF3, NO2, CN, halogen; R2 = R, OH, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, NH2, CO2R, aryl; R3 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, CO2R, aryl, NH2, CONR2, SO2R, SO2NHR2, aryl, CF3, NO2, CN, halogen; QR2R3 = cyclic, heterocyclic; Q = N, Cy X = bond, alkylene, oxoalkylene; X1 = bond, NR, Cy X2 = bond, (un)substituted alkylene; Y = CO1CR2)n, CR2, (un)substituted CH(OR); n = 0-3; Y1 = (un)substituted aryl, heterocyclyl; Z = (un)substituted (CR2)xOP(O)(OR)2] were prepared as potassium channel blockers for the treatment of glaucoma and other conditions which lead to elevated intraocular pressure. I have IC50 for inhibition of the maxi-K channel of 10-500 nM. Thus, the indazole II was prepared from 6-methoxy-1H-indazole-3-carboxaldehyde, 5-iodo-2-chloropyridine, K2CO3/DMSO/N2, and KOC(CH3)3, followed by phosphorylation.

IT 695206-75-8P 695206-77-0P 695206-89-4P
695206-91-8P 695207-09-7P 695209-00-7P
695209-11-1P 848420-11-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. as potassium channel blockers for treating ocular hypertension)

RN 695206-75-8 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-diethyl-3-[(6-(2-hydroxyethoxy)-3-pyridinyl)carbonyl]-6-methoxy- (CA INDEX NAME)

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 695207-09-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-(2-hydroxyethoxy)-3-pyridinyl)carbonyl]-6-methoxy-N,N-diprogyl- (CA INDEX NAME)



RN 695209-09-7 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-diethyl-3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695209-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 848420-11-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



IT 695206-79-2P 695206-81-6P 695206-83-8P
695206-85-0P 695206-87-2P 695207-91-1P
695207-93-3P 695207-99-9P 695208-01-6P
695208-03-2P 695208-09-4P 848420-14-4P
848420-15-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of indazole derivs. as potassium channel blockers for treating
vascular hypertension)
RN 695206-79-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)





RN 695207-91-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-99-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)

RN 695206-81-6 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-83-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(1-methylbutyl)- (CA INDEX NAME)



RN 695206-85-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-87-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(1-methylbutyl)- (CA INDEX NAME)



RN 695208-01-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-05-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-09-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 848420-14-4 CAPLUS
CN 1H-Indazole-3-acetamide, 6-methoxy-N,N-bis[3-methylbutyl)-3-[[6-[2-[phosphonooxy)ethyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)

RN 848420-15-5 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[[6-[2-[phosphonooxy)ethyl]-3-pyridinyl]carbonyl]- (CA INDEX NAME)

IT 848420-10-0P 848420-12-2P 848420-13-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as potassium channel blockers for treating
ocular hypertension)
RN 848420-10-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-6-methoxy-3-[[6-[2-[phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]- (CA INDEX NAME)



RN 848420-12-2 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[[6-[2-(phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]-N,N-dipropyl- (CA INDEX NAME)



RN 848420-13-3 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N,N-bis(3-methylbutyl)-3-[[6-[2-(phosphonooxy)ethoxy]-3-pyridinyl]carbonyl]- (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:1011963 CAPLUS
DOCUMENT NUMBER: 142:6526
TITLE: Preparation of indazolearboxamides as factor VIIa and/or factor Xa inhibitors
INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Laux, Volker; Urmann, Matthias; Bauer, Armin; Matter, Hans
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: Eur. Pat. Appl., 103 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479675	A1	20041124	EP 2003-11303	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238439	A1	20041125	AU 2004-238439	20040505
CA 2528220	A1	20041125	CA 2004-2528220	20040505
WO 2004101556	A1	20041125	WO 2004-EP4753	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1628972	A1	20060301	EP 2004-731155	20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
BR 2004010492	A	20060808	BR 2004-10492	20040505
JP 2006529942	T	20061228	JP 2006-529742	20040505
CN 2004800258424	A1	20041125	CN 2004-80025842	20040519
US 7160888	B2	20070109		
MX 2005PA12346	A	20060525	MX 2005-PA12346	20051116
PRIORITY APPLN. INFO.:			EP 2003-11303	A 20030519
			US 2003-507171P	P 20030930
			WO 2004-EP4753	W 20040505

OTHER SOURCE(S): CASREACT 142:6526; MARPAT 142:6526

GI

AB Title compds. [I, II; R = (substituted) mono- or bicyclic aryl, heterocyclyl; D = atoms to form a (substituted) 4-8 membered (heterocyclic) (aromatic) ring; R1 = H, (substituted) alkyl, aminoacetonylalkyl, alkoxyacetonylalkyl, aryl, heterocyclyl, etc.; R2 = bond, alkylene; V = (substituted) heterocyclyl, aryl; G = bond, (CR6)mNR1SO2(CR6)n, (CR6)mNR1SO2(CR6)nO, (CR6)mCH(OR)(CR6)n, (CR6)n, (CR6)nO(CR6)n, (CR6)mS(CR6)n, etc.; m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl, with provisos], were prepared Thus, 1-[5-(5-chlorothien-2-yl)isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-indazole-3-carboxylic acid (1-isopropylpiperidin-4-yl)amide (preparation outlined) inhibited factor Xa with Ki = 5 nM.

IT 797804-17-2P 797804-20-7P 797804-22-9P
797804-24-1P 797804-26-3P 797804-32-1P
797804-33-2P 797804-37-6P 797804-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indazolearboxamides as factor VIIa and/or
factor Xa inhibitors)

RN 797804-17-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(1-piperidinylcarbonyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-20-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(4-morpholinylcarbonyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-22-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 797804-24-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-33-2 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[[5-chloro-2-pyridinyl]amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-37-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-26-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (CA INDEX NAME)



RN 797804-32-1 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[[5-chloro-2-pyridinyl]amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 797804-38-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]- (CA INDEX NAME)



IT 797804-41-2P 797804-45-6P 797804-48-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)
RN 797804-41-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 797804-38-7
CMF C23 H27 Cl N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 797804-45-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-(5-chloro-2-pyridinyl)-3-[[4-(1-piperidinylmethoxy)phenyl]amino]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 797804-17-2
CMF C27 H25 Cl N6 O3

● x HBr

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 797804-48-9 CAPLUS
CN 1H-Indazole-5-carboxylic acid, 1-[2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, hydrobromide (1:1) (CA INDEX NAME)

ACCESSION NUMBER: 2004:430692 CAPLUS
DOCUMENT NUMBER: 141:7107
TITLE: Preparation of 1H-indazoles as K channel blockers for use in ophthalmic compositions for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Chen, Meng-Hsin; Liu, Luping; Natarajan, Swaminathan R.; Shen, Dong-Ming; Tymebor, Robert M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043354	A2	20040527	WO 2003-US34959	20031104
WO 2004043354	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2505127	A1	20040527	CA 2003-2505127	20031104
AU 2003287481	A1	20040603	AU 2003-287481	20031104
EP 1581503	A2	20051005	EP 2003-781722	20031104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006518742 T	20060810	JP 2005-507094	20031104
US 20060020000 A1	20060126	US 2003-530640	20050408
PRIORITY APPLN. INFO.:		US 2002-424730P P	20021108
		US 2003-500094P P	20030904
		WO 2003-US34959 W	20031104

OTHER SOURCE(S): MARPAT 141:7107
GI



I II

AB This invention relates to the preparation and use of title compds. I [wherein X = (CHR7)p, (CHR7)pCO; Y = CO(CHR2)n, CH2, CH(OR); Q = N or O, wherein R2 is absent when Q = O; R = H or alkyl; R2 = H, OH, (CH2)nO(CH2)nOR, COZR, NR2R3; or (un)substituted alkyl, alkenyl, alkoxy(alkyl), thioalkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl); R3 = H, NO2, CN, halo, (CH2)nCOZR, (CH2)NZR, (CH2)nSO2NR2, or (un)substituted alkyl, cycloalkyl(alkyl), heterocyclyl(alkyl), aryl(alkyl), alkoxy(alkyl), cwhaneoyl(alkyl), (CH2)nNHZ; R4 and R5 = independently H, alkoxy, OH, alkyl, acyl, CO2R, SO3H, C(CH2)nNR2, CF(CH2, CF3, NH2, NO2, CN, halo, etc.; R6 = H, CO2R, CONR2, or (un)substituted alkyl, aryl(alkyl); NR2, heterocyclyl(alkyl), arjloxy, cycloalkyl(alkyl), etc.; R7 = H, alkyl, (CH2)nOCR, CH2)nNR2; n = 0-3; n = 0-7; p = 0-3; and pharmaceutically acceptible salts, enantiomers, diastereomers, or mixts. thereof] and pharmaceutical compns. comprising them as potent K channel blockers for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient (no data). This invention also relates to the use of I to provide a neuroprotective effect to the eye of mammalian species, particularly humans (no data). For example, 3-benzoyl-6-methoxy-1H-indazole (preparation given) was N-alkylated with Me

bromocarbte in the presence of NaH in DMF and the product hydrolyzed using LiOH in THF to afford II. Compds. of the invention inhibited maxi-K

channels in TsA-201 cells with IC50 values < 20μM in a fluorescence assay and blocked the activity of maxi-K channels in human non-pigmented ciliary epithelial cells with IC50 values < 20μM in an electrophysiol. study.

IT 695209-09-7P 695209-11-1P

RL: BCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate preparation of 1H-indazoles as K channel blockers for use as

ophthalmic compns. for treating ocular hypertension)

RN 695209-09-7 CAPLUS

CN 1H-Indazole-1-acetamide, N,N-dimethyl-3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-

RN 695209-11-1 CAPLUS

CN 1H-Indazole-1-acetamide, 3-[(6-chloro-3-pyridinyl)carbonyl]-6-methoxy-N,N-

RN 695206-45-2 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-(2-thiazolyl)- (CA INDEX NAME)

RN 695206-47-4 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclohexyl-N-ethyl-6-methoxy- (CA INDEX NAME)

RN 695206-49-6 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-N-butyl-N-ethyl-6-methoxy- (CA INDEX NAME)

RN 695206-51-0 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclopentyl-6-methoxy-N-2-propenyl- (9CI) (CA INDEX NAME)

bis(3-methylbutyl)- (CA INDEX NAME)

IT 695206-45-2P 695206-47-4P 695206-49-6P 695206-51-0P 695206-52-1P 695206-54-3P 695206-56-5P 695206-58-7P 695206-64-5P 695206-66-7P 695206-67-8P 695206-69-0P 695206-71-4P 695206-75-8P 695206-77-0P 695206-79-2P 695206-81-6P 695206-83-8P 695206-85-0P 695206-87-2P 695206-89-4P 695206-91-8P 695206-93-0P 695206-95-2P 695206-97-4P, N-Cyclopropylmethyl-2-[3-[2,2-dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-propylacetamide 695206-99-6P, N-(Cyclobexylmethyl)-2-[3-[2,2-dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-ethylacetamide 695207-01-3P, 2-[3-[2,2-Dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-ethyl-N-(3-methylbutyl)acetamide 695207-09-1P, N-(3,3-Dimethylbutyl)-2-[3-[2,2-dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-ethylacetamide 695207-17-7P, N-Butyl-2-[3-[2,2-dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-propylacetamide 695207-15-9P, 2-[3-[2,2-Dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-ethyl-N-(3,3-thiazol-2-yl)acetamide 695207-17-1P, 2-[3-[2,2-Dimethylpropanoyl]-6-methoxy-1H-indazol-1-yl]-N-(3,4-dimethylpropyl)-N-ethylacetamide 695207-19-3P 695207-21-7P 695207-23-9P 695207-25-1P 695207-27-3P 695207-29-5P 695207-31-9P 695207-33-1P 695207-35-3P 695207-37-5P 695207-39-7P 695207-41-1P 695207-43-3P 695207-45-5P 695207-47-7P 695207-49-9P 695207-51-3P 695207-53-5P 695207-60-4P 695207-62-6P 695207-64-8P 695207-69-3P 695207-73-9P 695207-75-1P 695207-77-3P 695207-79-5P 695207-81-9P 695207-85-3P 695207-89-7P 695207-91-1P 695207-95-5P 695207-99-9P 695208-01-6P 695208-05-0P 695208-09-4P 695208-11-8P 695208-13-0P 695208-15-2P 695208-17-4P 695208-19-6P 695208-22-1P 695208-24-3P 695208-26-5P 695208-28-7P 695208-34-5P 695208-36-7P 695208-38-9P 695208-42-5P 695208-47-2P 695208-52-7P 695208-55-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(maxi-K blocker; preparation of 1H-indazoles as K channel blockers for use

in ophthalmic compns. for treating ocular hypertension)

RN 695206-52-1 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N,N-dipropyl- (CA INDEX NAME)

RN 695206-54-3 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-N,N-diethyl-6-methoxy- (CA INDEX NAME)

RN 695206-56-5 CAPLUS

CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-2-thiazolyl- (CA INDEX NAME)



RN 695206-58-7 CAPLUS
CN 1H-Indole-1-acetamide, 3-benzoyl-6-methoxy-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695206-64-3 CAPLUS
CN 1H-Indole-1-acetamide, N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-thiazolyl- (CA INDEX NAME)



RN 695206-66-5 CAPLUS
CN 1H-Indole-1-acetamide, N-cyclohexyl-N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)





RN 695206-77-6 CAPLUS
CN 1H-Indole-1-acetamide, 3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-79-2 CAPLUS
CN 1H-Indole-1-acetamide, N-butyl-N-ethyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-81-6 CAPLUS
CN 1H-Indole-1-acetamide, N,N-dibutyl-3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)

RN 695206-67-8 CAPLUS
CN 1H-Indole-1-acetamide, N-(2-ethyl-4-thiazolyl)-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695206-69-0 CAPLUS
CN 1H-Indole-1-acetamide, N-cyclopentyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 695206-71-4 CAPLUS
CN 1H-Indole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695206-75-8 CAPLUS
CN 1H-Indole-1-acetamide, N,N-dibutyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-83-8 CAPLUS
CN 1H-Indole-1-acetamide, 3-[[6-(hydroxymethyl)-2-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-85-0 CAPLUS
CN 1H-Indole-1-acetamide, N,N-dibutyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-87-2 CAPLUS
CN 1H-Indole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-89-4 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-[2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695206-91-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-[2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695206-93-0 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy- (CA INDEX NAME)



RN 695207-01-3 CAPLUS
CN 1H-Indazole-1-acetamide,
3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(3-methylbutyl)- (CA INDEX NAME)



RN 695207-09-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-13-7 CAPLUS
CN 1H-Indazole-1-acetamide,
N-butyl-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695206-95-2 CAPLUS
CN 1H-Indazole-1-acetamide,
3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-bis(2-methylpropyl)- (CA INDEX NAME)



RN 695206-97-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-(cyclopropylmethyl)-3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-N-propyl- (CA INDEX NAME)

RN 695206-99-6 CAPLUS
CN 1H-Indazole-1-acetamide,
N-(cyclobutylmethyl)-3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-15-9 CAPLUS
CN 1H-Indazole-1-acetamide,
3-(2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-17-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(2,2-dimethyl-1-oxopropyl)-N-(2,2-dimethylpropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695207-19-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclopentylcarbonyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-21-7 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(cyclopentylcarbonyl)-6-methoxy- (CA INDEX NAME)



RN 695207-23-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclopentylcarbonyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695207-25-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclohexylcarbonyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)





RN 695207-35-3 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-37-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)



RN 695207-39-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-butyl-N-ethyl- (CA INDEX NAME)

RN 695207-27-3 CAPLUS
CN 1H-Indazole-1-acetamide, N,N-dibutyl-3-(cyclohexylcarbonyl)-6-methoxy- (CA INDEX NAME)



RN 695207-29-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-(cyclohexylcarbonyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-31-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-33-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(3-hydroxypropoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695207-41-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-5-thiazolyl- (CA INDEX NAME)



RN 695207-43-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N,N-dipropyl- (CA INDEX NAME)



RN 695207-45-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-47-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-49-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-cyclohexyl-N-ethyl- (CA INDEX NAME)



RN 695207-51-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-N-propyl- (CA INDEX NAME)



RN 695207-53-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-N-ethyl-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695207-69-3 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-N-methyl-3-(2-methyl-1-oxopropyl)-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695207-73-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)-N-propyl- (CA INDEX NAME)



RN 695207-75-1 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N,N-dipropyl- (CA INDEX NAME)



RN 695207-60-4 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-62-6 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-[1-(2-thiazolyl)ethyl]- (CA INDEX NAME)



RN 695207-64-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-benzoyl-6-methoxy-N-methyl-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695207-77-3 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695207-79-5 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-(2-methyl-1-oxopropyl)-N-2-thiazolyl- (CA INDEX NAME)



RN 695207-81-9 CAPLUS
CN 1H-Indazole-1-acetamide, N-ethyl-N-(2-ethyl-4-thiazolyl)-6-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 695197-83-7 CAPLUS
CN 1H-Indazole-1-acetamide, 6-methoxy-3-[2-methyl-1-oxopropyl]-N-[1-[4-methyl-2-thiazolyl]ethyl]- (CA INDEX NAME)



RN 695197-99-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-[2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695197-91-1 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethoxy)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695208-55-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-09-4 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-N-ethyl-3-[[6-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy- (CA INDEX NAME)



RN 695208-11-8 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl]-N-ethyl-6-methoxy-N-(phenylmethyl)- (CA INDEX NAME)



RN 695207-95-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(hydroxymethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695207-99-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-01-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[[6-(1,1-difluoro-2-hydroxyethyl)-3-pyridinyl]carbonyl]-N-ethyl-6-methoxy- (CA INDEX NAME)



RN 695208-13-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl]-N-ethyl-6-methoxy-N-propyl- (CA INDEX NAME)



RN 695208-15-2 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl]-N-ethyl-6-methoxy-N-(1-methylethyl)- (CA INDEX NAME)



RN 695208-17-4 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl]-6-methoxy-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)

RN 695208-19-6 CAPLUS
CN 1H-Indazole-1-acetamide, N-[1,1-dimethylethyl)-3-[2,2-dimethyl-1-oxopropyl)-5-ethyl-6-methoxy- (CA INDEX NAME)

RN 695208-22-1 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 695208-24-3 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(2,3,4-thiadiazol-2-ylmethyl)- (CA INDEX NAME)

RN 695208-36-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy- (CA INDEX NAME)

RN 695208-38-9 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-bis(3-methylbutyl)- (CA INDEX NAME)

RN 695208-42-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl-N-(3-methylbutyl)- (CA INDEX NAME)



RN 695208-26-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-N-ethyl-6-methoxy-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 695208-28-7 CAPLUS
CN 1H-Indazole-1-acetamide, N-butyl-3-[2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl- (CA INDEX NAME)



RN 695208-34-5 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-6-methoxy-N,N-dipropyl- (CA INDEX NAME)



RN 695208-49-2 CAPLUS
CN 1H-Indazole-1-acetamide, N-(3,3-dimethylbutyl)-3-[2,2-dimethyl-1-oxopropyl)-6-methoxy- (CA INDEX NAME)



RN 695208-52-7 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-N,N-diethyl-6-methoxy- (CA INDEX NAME)



RN 695208-55-0 CAPLUS
CN 1H-Indazole-1-acetamide, 3-[2,2-dimethyl-1-oxopropyl)-6-methoxy-N-methyl-N-propyl- (CA INDEX NAME)

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds. [I; R1 = (CRaRb)nXj; Ra, Rb = independently H, C1-6 (un)substituted alkyl; X = N, C1-6 (un)substituted alkyl; n = 1-6; R2, R5 = independently H or halogen; R3, R4 = independently H, halogen, C1-6 (un)substituted alkyl; Q = heterocyclic group], useful in the treatment of viral infections, more particularly, for the treatment of respiratory syncytial virus infection, were prepared e.g., a four-step synthesis of II, starting with 2-(chloromethyl)benzimidazole, was given. The antiviral activity of these compds. against respiratory syncytial virus (RSV) was determined in HEp-2 (ATCC CCL 23) cells. The title compds. I, disclosed herein, show antiviral activity with EC50s between 50 μM and 0.001 μM.

IT 443985-43-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and use of heterocyclic substituted 2-methyl-benzimidazole antiviral agents)

RN 443985-43-1 CAPLUS

CN 1H-Indazole-3-carboxylic acid, 1-[2-[[2-[[2-[(methylsulfonyl)amino]ethyl]amino]phenyl]amino]-2-oxoethyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:282077 CAPLUS
DOCUMENT NUMBER: 119:282077
TITLE: Silver halide photographic material
INVENTOR(S): Arai, Kazumi; Kato, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05011384	A	19930122	JP 1991-191148	19910705
JP 2779712	B2	19980723		
PRIORITY APPLN. INFO.:			JP 1991-191148	19910705

AB The title material contains a compound represented by ED(Time)kYE [ED = moiety releasing [Time]kYE upon reaction with an oxidized developing agent; Time = divalent linking group; t = 0 or 1; Y = divalent group linked to ED(Time)t through a heteroatom; k = 2(t=0)or2(t=1); E = (substituted) aromatic or heterocyclic aromatic moiety which may consist of a single ring or fused rings; X = electron-attracting group]. The title material provides high contrast.

IT 151544-11-5

RL: USES (Uses)

(redox compound, in photog. material)

RN 151544-11-5 CAPLUS

CN 1H-Indazole-1-carboxylic acid, 3-[[[2-(methylsulfonyl)-4-nitrophenyl]amino]carbonyl]-, 2-[4-[[1H-benzotriazol-5-ylcarbonyl]amino]phenyl]hydrazide (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:556148 CAPLUS
DOCUMENT NUMBER: 137:125159
TITLE: Preparation and antiviral activity of heterocyclic substituted 2-methylbenzimidazole antiviral agents
INVENTOR(S): Yu, Kap-Long; Carvalho, Rita L.; Combrink, Keith D.; Gulgeze, Hatice Belgin; Shi, Ny; Wang, Xiangdong; Meanwell, Nicholas; Venables, Brian Lee; Zhang, Ti; Pearce, Bradley C.; Yin, Zhiwei; Thoring, Jan Willem
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020099208	A1	20020725	US 2001-974012	20011116
US 6774134	B2	20040810		
WO 2002062290	A2	20020815	WO 2001-US45149	20011116
WO 2002062290	A3	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002257794	A1	20020819	AU 2002-257794	20011116
EP 1343499	A2	20030917	EP 2001-270146	20011116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520297	T	20040708	JP 2002-562298	20011116
US 20040067997	A1	20040408	US 2003-643411	20030819
US 6844342	B2	20050118		
PRIORITY APPLN. INFO.:			US 2000-251739P	P 20001220
			US 2001-974012	A3 20011116
			WO 2001-US45149	W 20011116

OTHER SOURCE(S): MARPAT 137:125159
GI



L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:29827 CAPLUS
DOCUMENT NUMBER: 118:29827
ORIGINAL REFERENCE NO.: 118:5357a,5360a
TITLE: Silver halide photographic material
INVENTOR(S): Yagihara, Morio; Okamura, Hisashi; Kato, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04136838	A	19920511	JP 1990-258925	19900928
PRIORITY APPLN. INFO.:			JP 1990-258925	19900928

AB In the title material comprising one or more silver halide emulsion layers, the said silver halide emulsion layers or one or more hydrophilic colloid layers contain a redox compound which releases a nucleating development inhibitor upon oxidation. The title material gives high-quality images.
IT 145911-02-7
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials containing)
RN 145911-02-7 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 3-[[4-(trifluoroacetyl)anilino]carbonyl]-, 2-(4-butylphenyl)hydrazide (CA INDEX NAME)



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:521408 CAPLUS
DOCUMENT NUMBER: 117:121408
ORIGINAL REFERENCE NO.: 117:20937a,20936a
TITLE: Silver halide photographic materials
INVENTOR(S): Ka., Kazumu; Okamura, Hisashi; Katoh, Kazunobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 75 pp.
CODEN: EPXULW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 479156	A1	19920408	EP 1991-116543	19910927
EP 479156	B1	19940112		
R: DE, GB				
JP 04136840	A	19920511	JP 1990-258928	19900928
US 5252438	A	19931012	US 1991-767680	19910927
PRIORITY APPLN. INFO.:			JP 1990-258928	A 19900928

OTHER SOURCE(S): MARPAT 117:121408
AB A photog. material is described comprising KD-(Time)t-Y-L-X or R1NA1NA2O1 (Time)t Y-L-X [KD = releasing group; Time = divalent linking group; t = 0,
1; Y = divalent group containing heteroatom, bonded to (Time); L = group cleavable on coupling reaction; X = monovalent fractional group having development inhibiting effect; R1 = alIphatic, aromatic group; G1 = CO, COCO,
CS, C(:NG2R2), P(:O)(G2R2)-, G2 = bond, O, S, NR3; R2 = H, R; of A1 and A2, one of them is R, and the other one is R, aryl, alkylsulfonyl, arylsulfonyl). The material is useful in formation of ultrahard neg. images by photoorgh. processes.
IT 143282-98-9
RL: USES (Uses)
(redox compound, for photog. emulsion)
RN 143282-98-9 CAPLUS
CN 1H-Indazole-1-carboxylic acid, 3-[[(4-nitrobenzoyl)oxy]methyl]-, 2-phenylhydrazide (CA INDEX NAME)



L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:638810 CAPLUS
DOCUMENT NUMBER: 117:238810
ORIGINAL REFERENCE NO.: 117:40225a,40226a
TITLE: Silver halide photographic material and image forming method using that material
INVENTOR(S): Katoh, Kazunobu; Okamura, Hisashi; Yagihara, Morio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 83 pp.
CODEN: EPXULW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 480264	A1	19920415	EP 1991-116544	19910927
EP 480264	B1	20000209		
R: DE, FR, GB				
JP 04126843	A	19920511	JP 1990-258924	19900928
JP 2843577	B2	19990310		
US 5278589	A	19940111	US 1991-763702	19910923
CA 2052096	A1	19920329	CA 1991-2052096	19910924
PRIORITY APPLN. INFO.:			JP 1990-258924	A 19900928

AB Photog. halftone images of outstanding quality are obtained using a photog. film containing a first hydrazine derivative capable of releasing a
development inhibitor as a result of oxidation with the developer (at least a
portion of this inhibitor is released into a developer where it reacts with the developing agent and changes into a compound with little inhibiting
effect), and (optionally) a second hydrazine derivative which has nucleating
effect.
IT 142554-90-2
RL: USES (Uses)
(photog. film for halftone image production containing)
RN 142554-90-2 CAPLUS
CN 1H-Indazole-1,3-diacarboxylic acid, 5-nitro-, 3-(2-hydroxypropyl) ester, 1-[2-[4-[[2-[4-[[(4-hydroxyphenyl)sulfonyl]phenoxy]-1-oxododecyl]amino]phenyl]hydrazide] (CA INDEX NAME)

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              82.23     291.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                             -12.00     -12.00

STN INTERNATIONAL LOGOFF AT 06:38:32 ON 01 MAY 2008
```